Compare LBRX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | EVMN |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 892.4M |
| IPO Year | N/A | N/A |
| Metric | LBRX | EVMN |
|---|---|---|
| Price | $23.91 | $24.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $49.00 | $44.17 |
| AVG Volume (30 Days) | 181.2K | ★ 988.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $13.89 |
| 52 Week High | $25.60 | $33.20 |
| Indicator | LBRX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 47.92 |
| Support Level | $22.34 | $15.25 |
| Resistance Level | $24.70 | $33.20 |
| Average True Range (ATR) | 1.26 | 2.54 |
| MACD | -0.14 | -0.67 |
| Stochastic Oscillator | 51.76 | 22.33 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.